** Berenberg downgrades French testing company Eurofins
Scientific ERF.PA to "hold" from "buy", citing disappointing
growth dynamics and lack of near-term catalysts for the stock
** The broker cuts its PT by 29% to EUR 53, vs EUR 46.08 as of
Tuesday's close
** It says top-line growth remains under pressure, particularly
in the soft pharmaceuticals market, and expects this weakness to
persist into H1 2025
** This leads to concerns over the company's ability to achieve
its mid-term organic growth target of 6.5%, it adds
** "While we see potential for EBITDA margin improvement and
free cash flow upside in FY25, we think better equity stories
exist elsewhere," the broker says
** Out of 16 analysts that cover Eurofins, five rate the stock
"strong buy" or "buy", seven "hold" and four "strong sell" or
"sell"
(Reporting by Johan Bodinier in Gdansk)
((johangeorgesroger.bodinier@thomsonreuters.com))